Focal myocarditis associated with immune checkpoint inhibitor therapy.

Hayashizaki, Mizuki; Omote, Kazunori; Tsuneta, Satonori; Nagai, Toshiyuki; Anzai, Toshihisa

Hayashizaki, Mizuki; Omote, Kazunori; Tsuneta, Satonori; Nagai, Toshiyuki; Anzai, Toshihisa.

Afiliação

Hayashizaki M; Department of Cardiovascular Medicine, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
Omote K; Department of Cardiovascular Medicine, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
Tsuneta S; Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, Japan.
Nagai T; Department of Cardiovascular Medicine, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.
Anzai T; Department of Cardiovascular Medicine, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita-15 Nishi-7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.

Eur Heart J Cardiovasc Imaging ; 24(12): e308, 2023 11 23.

Article em En | MEDLINE | ID: mdl-37694290

Assuntos

Antineoplásicos Imunológicos; Miocardite; Humanos; Miocardite/induzido quimicamente; Miocardite/diagnóstico por imagem; Inibidores de Checkpoint Imunológico; Antineoplásicos Imunológicos/efeitos adversos; Imunoterapia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Antineoplásicos Imunológicos / Miocardite Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Eur Heart J Cardiovasc Imaging Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google